K Robin Yabroff
Overview
Explore the profile of K Robin Yabroff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
339
Citations
13078
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nogueira L, Yabroff K, Yates E, Shultz J, Valdez R, Nori-Sarma A
J Natl Cancer Inst
. 2025 Mar;
PMID: 40064312
Background: Wildfires pose substantial health and safety threats to patients recovering from lung cancer surgery. Without specific disaster preparedness guidelines, surgical oncologists might resort to improvisational strategies, such as extending...
2.
Hu X, Kwon Y, Jiang C, Fan Q, Shi K, Zheng Z, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401935.
PMID: 40053887
Purpose: Early integration of specialized palliative care (PC) is recommended by clinical guidelines for advanced-stage cancers, but real-world evidence of its use is limited. We examined the recent trend of...
3.
Jiang C, Nipp R, Hong A, Shih Y, Xing J, Mullins M, et al.
JAMA Netw Open
. 2025 Mar;
8(3):e250008.
PMID: 40029662
No abstract available.
4.
Kwon Y, Hu X, Shi K, Zhao J, Jiang C, Fan Q, et al.
JAMA Health Forum
. 2025 Feb;
6(2):e245436.
PMID: 39982714
Importance: Considerable efforts have been dedicated to improving the quality of end-of-life care among patients with advanced cancer in the past decade. Whether the quality has shifted in response to...
5.
Hu X, Jiang C, Yabroff K, Lipscomb J, Graetz I
Health Serv Res
. 2025 Feb;
:e14436.
PMID: 39972532
Objective: To examine the trend in Immune Checkpoint Inhibitor (ICI) use before and after FDA approval in 2015 for patients with metastatic non-small cell lung cancer (NSCLC), and whether vertical...
6.
Fan Q, Dong W, Schafer E, Wagle N, Zhao J, Shi K, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39898816
The COVID-19 pandemic disrupted healthcare and reduced cancer diagnoses in the U.S., raising concerns about its impact on time-to-treatment initiation (TTI), a critical factor for survival. This study examined the...
7.
Zhang L, Yang N, Shen T, Sun X, Yabroff K, Han X
Am J Prev Med
. 2025 Jan;
PMID: 39824449
Introduction: This study aimed to examine the association of county-level racial and economic residential segregation with mortality rates in the U.S. between 2018 and 2022. Methods: Residential segregation was measured...
8.
9.
Chen M, Zhao J, Ogongo M, Han X, Zheng Z, Yabroff K
JCO Oncol Pract
. 2025 Jan;
21(1):78-88.
PMID: 39793554
Purpose: Financial hardship is common among cancer survivors and has been associated with worse physical and mental health in selected subpopulations. We comprehensively examined associations of financial hardship with multiple...
10.
Han X, Ogongo M, Tian F, Zhao J, Zheng Z, Liu Z, et al.
Cancer Causes Control
. 2024 Dec;
PMID: 39633205
Purpose: Cancer and its treatments may accelerate the aging process. However, accelerated aging among cancer survivors is not well understood. This study examines accelerated aging among adults with and without...